Every earnings call for NATCOPHARM — management tone, guidance, KPIs and promise tracking, quarter by quarter.
NATCOPHARM · 7 transcripts · Healthcare · latest Q4 FY26Natco Pharma Limited has 7 earnings calls on record here, a Healthcare company, most recently Q4 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
FY26 Consolidated Revenue ₹4,376 cr (−9% YoY); FY26 Consolidated Net Profit ₹1,418 cr (−25% YoY). Full year FY26 consolidated net profit of INR 1,418.5 crores.
Read full transcript & analysisConsolidated Revenue ₹705 cr (+8% YoY); EBITDA ₹217 cr; EBITDA Margin 30.7%. Consolidated revenue of ₹705.4 crores, up 8.34% YoY.
Read full transcript & analysisConsolidated total revenue for Q2 FY26 was Rs 1,463 crores, up from Rs 1,434.9 crores in Q2 FY25.
Read full transcript & analysisConsolidated total revenue for Q1 FY26 was INR1,390.6 crores, a slight decline from INR1,410.7 crores in Q1 FY25.
Read full transcript & analysisNatco Pharma proposes to acquire a 35.75% stake in Adcock Ingram Holdings Limited.
Read full transcript & analysisConsolidated total revenue for Q3 FY25 was ₹651.1 crores, down from ₹795.6 crores in Q3 FY24, representing an 18.16% YoY decline.
Read full transcript & analysisConsolidated total revenue of INR1,434.9 crores, up 35.3% YoY.
Read full transcript & analysis